Skin cancer is by far the most common form of cancer.  In the U.S., there will be over one million cases diagnosed this year alone.

Melanoma is one of the most serious types of skin cancer.  And if it isn’t caught early enough, it can metastasize, most likely in one’s bones.

Until recently, there wasn’t much that could be done then.  But new therapies offer some hope for advanced melanoma patients.

One of these promising advanced combines a pair of drug being developed by GlaxoSmithKline.  Researchers at Moffitt Cancer Center found that combining debrafenib and trametinib extend some previously difficult to treat patients with advanced, metastasized melanoma by almost 40%.

Now before everyone get’s too excited, that means the average patient’s remission is only extended from 5.5 months to 9.5 months.  But at least it’s a start!

I became interested in this project after reading about it in my local Tampa Bay Times.  Several things caught my eye.  I’m a melanoma survivor, and Moffitt is where I see both my melanoma and multiple myeloma specialists.

When I speak to support groups around the country, I often kid about how lyrical it is to have both myeloma and now melanoma.  “Myeloma and melanoma; isn’t that poetic?”  I then usually pause and add,  “How lyrical!”

I was diagnosed with melanoma one year ago this month.  I share more about my experience with skin cancer today on my daily myeloma blog:

For me, October will always be melanoma month

Check-it-out if you get a chance.

Until then, feel good and keep smiling!  Pat

3 thoughts on “New drug combination extends remission in patients with advanced melanoma

  1. There are more good stuff for melanoma in the pipe. For example, Novartis LGX818+MEK162, Roche MEK inhibitor GDC0973, HSP90 inhibitors… anti-PD1 monoclonal antibodies, TIL therapy and so in. If only clinical trials would be more flexible….

Leave a Reply